Resources Repository
-
OrganizationWeb Portal 2024ISPOR
Founded in 1995 as an international multidisciplinary professional membership society, the International Society for Pharmacoeconomics …
Founded in 1995 as an international multidisciplinary professional membership society, the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) exists to advance the policy, science, and practice of pharmacoeconomics (health economics) and health outcomes research. ISPOR publishes Value in Health, which contains original research articles in the areas of economic evaluation, outcomes research, and conceptual, methodological, and health policy articles. Beyond health economics and outcomes research resources, tools of ISPOR include strategic initiatives, publications, and member…
Preferences/Values | Cost-Effectiveness Analysis | Costing Methods | Health Outcomes | Value of Information | Health/Medicine | Economics/Finance | Priority Setting/Ethics | Mathematical Models | Technology Assessment | Operations Research | Infectious Diseases | Maternal/Reproductive Health | Child/Nutrition | Chronic Disease/Risk | Health Systems | Policy/Regulation | Business/Industry | Science/Technology | Global -
ArticlePublication 2015Broader Economic Impact of Vaccination: Reviewing and Appraising the Strength of Evidence
Economic evaluations of public health programs such as immunization often consider only direct health benefits and …
Economic evaluations of public health programs such as immunization often consider only direct health benefits and medical cost savings. Evidence linking immunization to important benefits in indicators such as childhood development, household behavior, and other macro-economic data are unclear. A conceptual framework of the pathways between immunization and these broader economic benefits was developed through expert consultation. The authors obtained articles from previous reviews, snowballing, and expert consultation, and associated them with one of the pathways and assessed them using modified Grading…
Evidence Synthesis | Preferences/Values | Benefit-Cost Analysis | Cost-Effectiveness Analysis | Costing Methods | Health/Medicine | Economics/Finance | Priority Setting/Ethics | Infectious Diseases | Social Determinants | Education/Labor -
OrganizationWeb Portal 2024Institute for Clinical and Economic Review (ICER)
ICER is a non-profit organization that evaluates evidence on a range of topics including the value …
ICER is a non-profit organization that evaluates evidence on a range of topics including the value of medical tests, treatments and delivery system innovations and moves that evidence into action to improve the health care system. To accomplish this goal ICER performs analyses on effectiveness and costs, supports specific programs, and develops reports using innovative methods that make it easier to translate evidence into decisions that can align efforts to use evidence to drive improvements in both…
Evidence Synthesis | Preferences/Values | Cost-Effectiveness Analysis | Value of Information | Health/Medicine | Economics/Finance | Priority Setting/Ethics | Technology Assessment | Infectious Diseases | Chronic Disease/Risk | Mental Health | Health Systems | Business/Industry | Government/Law | Science/Technology | North America | Europe -
OrganizationWeb Portal 2024Agency for Healthcare Research and Quality (AHRQ)
The Agency for Healthcare Research and Quality (AHRQ) is the nation's lead federal agency for …
The Agency for Healthcare Research and Quality (AHRQ) is the nation's lead federal agency for research on health care quality, costs, outcomes and patient safety. AHRQ is the health services research arm of the U.S. Department of Health and Human Services (HHS), complementing the biomedical research mission of its sister agency, the National Institutes of Health. The agency is home to research centers that specialize in major areas of health care research, including: clinical practice…
Test Performance | Cost-Effectiveness Analysis | Costing Methods | Health Outcomes | Health/Medicine | Economics/Finance | Decision Analysis | Technology Assessment | Infectious Diseases | Maternal/Reproductive Health | Child/Nutrition | Chronic Disease/Risk | Mental Health | Injuries/Accidents | Social Determinants | Health Systems | Policy/Regulation | Government/Law | Science/Technology | North America -
ArticlePublication 2022Comparative Health Systems Analysis of Differences in Catastrophic Health Expenditure
The growing burden of non-communicable diseases (NCDs) in low- and middle-income countries may have implications …
The growing burden of non-communicable diseases (NCDs) in low- and middle-income countries may have implications for health system performance in the area of financial risk protection, as measured by catastrophic health expenditure (CHE). This article compares non-communicable diseases catastrophic health expenditure to the CHE cases caused by communicable diseases across health systems to examine whether: (1) disease burden and catastrophic health expenditure are linked, (2) Catastrophic health expenditures secondary to NCDs disproportionately affect wealthier households and (3) whether the drivers…
Evidence Synthesis | Cost-Effectiveness Analysis | Costing Methods | Health/Medicine | Economics/Finance | Infectious Diseases | Chronic Disease/Risk | Health Systems | Global -
OrganizationWeb Portal 2024Society for Benefit-Cost Analysis
The Society for Benefit-Cost Analysis (SBCA), founded in 2007, works to improve the theory and …
The Society for Benefit-Cost Analysis (SBCA), founded in 2007, works to improve the theory and practice of benefit-cost analysis and support evidence-based policy decisions. It addresses policy areas including public health, transportation, criminal justice, education, energy, environmental quality, homeland security, and poverty. Members include scholars and practitioners from around the world, who work in government, academia, nonprofits and private industry. Its members represent numerous disciplines such as economics, law, engineering, public policy, decision science, and…
Preferences/Values | Benefit-Cost Analysis | Costing Methods | Health/Medicine | Economics/Finance | Priority Setting/Ethics | Social Determinants | Environmental Health | Policy/Regulation | Business/Industry | Climate/Environment | Energy/Engineering | Education/Labor | Food/Agriculture | Government/Law | Military/Defense | Science/Technology | Global | Critical Thinking/Analysis -
Working PaperPublication 2018Valuing Mortality Risk Reductions in Global Benefit-Cost Analysis
Increasing life expectancy is a major goal of many policies implemented around the world. As …
Increasing life expectancy is a major goal of many policies implemented around the world. As a result, the value of reducing mortality risk has been extensively studied and several organizations have developed recommendations for estimating these values in benefit-cost analysis. However, both the recommendations and the underlying research primarily address high-income settings, raising questions about the extent to which the results are applicable in low- and middle-income countries. The recommendations are also diverse, reflecting differing…
Preferences/Values | Benefit-Cost Analysis | Health Outcomes | Health/Medicine | Economics/Finance | Priority Setting/Ethics | Decision Analysis | Social Determinants | Policy/Regulation | Global -
Working PaperPublication 2018Valuing Nonfatal Health Risk Reductions
This paper explores approaches for valuing nonfatal risk reductions associated with policy choices in low- …
This paper explores approaches for valuing nonfatal risk reductions associated with policy choices in low- and middle-income countries. The approach for valuation ideally would be based on estimates of individuals’ willingness to pay for changes in their own risks. However, high quality valuation research is not available for many nonfatal conditions even in high-income settings. Typically, two approaches are used either alone or in combination as rough proxies. The first involves applying an estimate of…
Preferences/Values | Benefit-Cost Analysis | Health Outcomes | Health/Medicine | Economics/Finance | Priority Setting/Ethics | Decision Analysis | Social Determinants | Policy/Regulation | Global | Critical Thinking/Analysis -
ArticlePublication 2018Equity Impact Vaccines May Have on Averting Deaths and Medical Impoverishment
In this analysis, authors estimated the number of deaths averted and the number of cases …
In this analysis, authors estimated the number of deaths averted and the number of cases of medical impoverishment averted of ten antigens and their corresponding vaccines across income quintiles for forty-one low- and middle-income countries. The study found that vaccines administered between 2016 and 2030 would prevent 36 million deaths. Vaccines will have the greatest impact on reducing cases of poverty caused by hepatitis B, helping an estimated 14 million people avoid medical impoverishment. An…
Cost-Effectiveness Analysis | Costing Methods | Health Outcomes | Health/Medicine | Economics/Finance | Priority Setting/Ethics | Mathematical Models | Infectious Diseases | Child/Nutrition | Global Governance | Science/Technology | Sub-Saharan Africa | Middle East & North Africa | Asia & Pacific